
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics is a biopharmaceutical company with a positive outlook due to its potential for high growth and large upside opportunities in the ~$billion breast cancer market. Despite the risks associated with clinical trials, the company's recent filing of its IND application for (Z)-Endoxifen in Metastatic Breast Cancer and its efforts to expand its indications beyond metastatic breast cancer demonstrate its strong progress and potential for success in the future. Additionally, the company's current valuation is attractive, and it has one main therapeutic drug candidate in development, making it a promising investment opportunity.
Bears say
Atossa Therapeutics is facing several fundamental risks, including potential balance sheet and liquidity issues, the possibility of product candidates failing to meet safety and efficacy standards in clinical trials, and difficulties in gaining regulatory approvals and commercializing products due to competition and changing macroeconomic factors. The recent appointment of Mark Daniel as Chief Financial Officer may bring some positive changes, however, with his strong background in finance and experience in the life science industry.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares